Morepen Laboratories Ltd management interview: Morepen Labs Q2 Earnings: Revenue Near ₹755 Crore, Half-Year EBITDA At ₹220 Crore | Business News
ET Now, 2026-10-29. Video: https://www.youtube.com/watch?v=sS5Ik4HCW7Q
- CDMO scale-up: CDMO moved from validation to commercial supply, rising from 10% of revenue last quarter to 52% of revenue between API and CDMO. Management described the supply contracts as long-term, with better quarter-on-quarter visibility.
- API recovery: API EBITDA margins rose from 8 to 12%, with 12 to 13% already clocked; management expects new molecules and export focus to support further improvement. New molecules increased from 14% to 25% of API revenue, and 76% of API revenue is now from exports.
- Medical devices: The chronic-care franchise spans BP monitors and glucometers, where Morepen says it is the market leader. It has a 20 million installed base of glucometers and sells at least 500 million strips every year.
- Returns and investment: Management cited ROE of more than 15-16% and ROCE of more than 18%, alongside improving debtors and cash flow. It said these gains support investment in capacity, research and an innovation hub; the foundation stone has been laid for a new civil block.
- Growth outlook: Revenue was around ₹754 crore, ₹755 crore, and EBITDA was ₹132 crore versus ₹82 crore last quarter; half-year EBITDA was ₹220 crore. Management gave no quarter-by-quarter guidance, but said the direction was positive for API and CDMO, with ₹311 crore already completed against an order to be fulfilled within 12 to 15 months.